{
  "eval_id": "S36",
  "eval_file": "evals/single/S36.json",
  "timestamp": "2025-09-18T17:14:52.152307+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is approved for adults with HR-positive, HER2-negative metastatic breast cancer who have received endocrine therapy and at least two prior lines of chemotherapy, including a CDK4/6 inhibitor. The key on-label point is its use after these prior treatments in this settingâ€”please send the SmPC or EMA EPAR by email if you want to highlight a specific detail."
}